The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells.
colon cancer
de novo fatty acid synthesis
glutaminolysis
glycolysis
metabolism
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
14
12
2019
accepted:
16
04
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
ppublish
Résumé
Cancer upregulates glycolysis, glutaminolysis and lipogenesis, and induces a catabolic state in patients. The concurrent inhibition of both tumor anabolism and host catabolism, and the energetic consequences of such an approach, have not previously been fully investigated. In the present study, CT26.WT murine colon cancer cells were treated with the combination of anti-anabolic drugs orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine (DON; OLD scheme), which are inhibitors of the
Identifiants
pubmed: 32782623
doi: 10.3892/ol.2020.11838
pii: OL-0-0-11838
pmc: PMC7400019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3053-3060Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Science. 2000 Sep 29;289(5488):2363-6
pubmed: 11009425
Ann Surg Oncol. 1994 Jul;1(4):321-32
pubmed: 7850531
Oncotarget. 2010 Dec;1(8):734-40
pubmed: 21234284
J Surg Res. 1996 Mar;61(2):317-22
pubmed: 8656602
J Clin Lab Anal. 2012 Sep;26(5):328-35
pubmed: 23001977
Nat Struct Mol Biol. 2007 Aug;14(8):704-9
pubmed: 17618296
Nutr Cancer. 2015;67(1):12-26
pubmed: 25513730
QJM. 2016 Jun;109(6):367-72
pubmed: 26428335
World J Gastroenterol. 2006 Jun 28;12(24):3810-3
pubmed: 16804963
Oncol Lett. 2019 Dec;18(6):6909-6916
pubmed: 31788130
Res Nurs Health. 2005 Feb;28(1):56-66
pubmed: 15625704
Expert Opin Investig Drugs. 2018 May;27(5):475-489
pubmed: 29723075
Oncogene. 2010 Jan 21;29(3):313-24
pubmed: 19881548
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Aging (Albany NY). 2019 Sep 13;11(17):7197-7205
pubmed: 31518336
Postgrad Med. 2012 Jul;124(4):197-205
pubmed: 22913908
Biochem J. 2016 Jun 1;473(11):1503-6
pubmed: 27234586
Biomed Res Int. 2015;2015:690492
pubmed: 26425550
Int J Oncol. 2004 Mar;24(3):505-12
pubmed: 14767534
Lung Cancer. 2018 Dec;126:32-40
pubmed: 30527190
Surgery. 1986 Aug;100(2):188-97
pubmed: 3090723
Oncogene. 2006 Aug 7;25(34):4777-86
pubmed: 16892090
Sci Rep. 2014 Jan 23;4:3827
pubmed: 24451979
Cancer Res. 2004 Mar 15;64(6):2070-5
pubmed: 15026345
World J Gastroenterol. 2004 Apr 15;10(8):1132-6
pubmed: 15069712
Curr Drug Saf. 2013 Nov;8(5):333-48
pubmed: 24215311
Nat Rev Cancer. 2007 Oct;7(10):763-77
pubmed: 17882277
Lipids Health Dis. 2018 May 24;17(1):122
pubmed: 29793481
Front Physiol. 2013 Sep 03;4:237
pubmed: 24027532
J Clin Endocrinol Metab. 1995 Jul;80(7):2082-7
pubmed: 7608259
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):E7697-E7706
pubmed: 28847964
Surg Today. 1996;26(4):271-5
pubmed: 8727949
Int J Biochem. 1993 Dec;25(12):1749-55
pubmed: 8138012
Diabetes Care. 2011 Dec;34(12):2496-501
pubmed: 21994429
Oncol Rep. 2015 Sep;34(3):1533-42
pubmed: 26134042
Oncotarget. 2015 Aug 7;6(22):18891-904
pubmed: 25970773
Cancer Res. 1985 Oct;45(10):4925-31
pubmed: 3896470
Dimens Crit Care Nurs. 2004 Nov-Dec;23(6):237-43
pubmed: 15586034
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Am J Cancer Res. 2017 May 01;7(5):1107-1135
pubmed: 28560061
Growth Horm IGF Res. 2000 Dec;10(6):297-305
pubmed: 11161960
Semin Cell Dev Biol. 2020 Feb;98:63-70
pubmed: 31129171
Surgery. 1991 Apr;109(4):459-67
pubmed: 2008651
Int J Oncol. 2017 Feb;50(2):736-744
pubmed: 28101572
Cancer Res Treat. 2019 Apr;51(2):538-546
pubmed: 29986576
Ann Surg. 1987 Jul;206(1):56-61
pubmed: 3606231